Switching from Emicizumab to Marstacimab for Severe Hemophilia A
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests if switching from emicizumab to a new medicine called marstacimab is safe and effective for people with severe hemophilia A. You must have been on emicizumab for at least 6 months and not have a history of blood clots or heart disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Male, age 12 to under 75, and weigh at least 35 kg (about 77 lbs).
- Diagnosed with severe hemophilia A (factor VIII less than 1%) with no inhibitors.
- Currently taking emicizumab at a standard dose for at least 6 months.
- No history of blood clots, heart disease, or stroke.
- No other bleeding disorders besides hemophilia A.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how your body’s anti-factor VIII antibodies change while you are treated with emicizumab for severe hemophilia A. The goal is to better understand the immune response during treatment and whether it relates to how well therapy works.
This trial tests a new form of factor VIII that lasts longer in the body, so you may need fewer infusions. It is for men with severe hemophilia A who have already used factor VIII products for at least 150 days.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
This Phase 1 trial studies how well and safely emicizumab works for people with severe von Willebrand disease (VWD) or VWD plus hemophilia A. Emicizumab is a preventive medicine given regularly to reduce bleeding risk.
This registry study follows people with hemophilia A or B who are taking marstacimab as their regular preventive treatment. It aims to understand how the medicine works in real life and how patients feel during treatment.
This Phase 3 study tests marstacimab, a new medicine, to help prevent or better control bleeding in children and teens with hemophilia A or hemophilia B. You may be eligible if your child’s past records show ongoing bleeding and treatment with factor replacement (or specific inhibitor-related patterns).
Hear when a new Severe Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.